Furthermore, we demonstrate a requirement of CSNK1D for GLI-dependent TIC properties in vitro and in vivo, and introduce a novel CSNK1D inhibitor with therapeutic activity against GLI-driven cancer cells. This evidence concerns the gene CSNK1D and cancer.